Macrophages in immunoregulation and therapeutics

S Chen, AFUH Saeed, Q Liu, Q Jiang, H Xu… - … and Targeted Therapy, 2023 - nature.com
Macrophages exist in various tissues, several body cavities, and around mucosal surfaces
and are a vital part of the innate immune system for host defense against many pathogens …

The development of COVID-19 treatment

Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

The signal pathways and treatment of cytokine storm in COVID-19

L Yang, X Xie, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …

The JAK/STAT signaling pathway: from bench to clinic

X Hu, J Li, M Fu, X Zhao, W Wang - Signal transduction and targeted …, 2021 - nature.com
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or …

EW Ely, AV Ramanan, CE Kartman… - The Lancet …, 2022 - thelancet.com
Summary Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown
efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) …

Baricitinib plus remdesivir for hospitalized adults with Covid-19

AC Kalil, TF Patterson, AK Mehta… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background Severe coronavirus disease 2019 (Covid-19) is associated with
dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus …

[HTML][HTML] A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

DJ Ahern, Z Ai, M Ainsworth, C Allan, A Allcock… - Cell, 2022 - cell.com
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete
description of specific immune biomarkers. We present here a comprehensive multi-omic …

Two years into the COVID-19 pandemic: lessons learned

SJR da Silva, JCF do Nascimento… - ACS infectious …, 2022 - ACS Publications
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …

SARS‐CoV‐2 sensing by RIG‐I and MDA5 links epithelial infection to macrophage inflammation

LG Thorne, AK Reuschl, L Zuliani‐Alvarez… - The EMBO …, 2021 - embopress.org
SARS‐CoV‐2 infection causes broad‐spectrum immunopathological disease, exacerbated
by inflammatory co‐morbidities. A better understanding of mechanisms underpinning virus …

[HTML][HTML] COVID-19 and the human innate immune system

JL Schultze, AC Aschenbrenner - Cell, 2021 - cell.com
The introduction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the
human population represents a tremendous medical and economic crisis. Innate immunity …